Related Experiment Video
Updated: Aug 8, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Dendritic cells in clinical trials for multiple myeloma
Volker L Reichardt1, Peter Brossart
1Department of Hematology, Oncology, Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.
Insights
Idiotype-based dendritic cell (Id/DC) vaccination is a feasible treatment for multiple myeloma, inducing specific immunity in patients. Future research will explore advanced dendritic cell immunization strategies.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Multiple myeloma exhibits a unique tumor antigen, the idiotype, making it a target for specific therapies.
- Previous studies in non-Hodgkin's lymphoma (NHL) showed promise with dendritic cell vaccination.
- Dendritic cell-based vaccination for multiple myeloma was initiated in 1995.
Purpose of the Study:
- To summarize published and ongoing clinical trials of idiotype-based dendritic cell (Id/DC) vaccination in multiple myeloma patients.
- To assess the feasibility and immunogenicity of Id/DC vaccination in this patient population.
Main Methods:
- Review of published clinical trials involving Id/DC vaccination for multiple myeloma.
- Analysis of ongoing clinical trials investigating Id/DC vaccination strategies.
- Focus on patient cohorts, vaccination protocols, and immune response assessments.
Main Results:
- Id/DC vaccination is feasible in multiple myeloma patients, even those heavily pretreated.
- Myeloma-specific immunity can be successfully induced through Id/DC vaccination.
- Encouraging data from NHL patients supported the initiation of trials in multiple myeloma.
Conclusions:
- Idiotype-based dendritic cell vaccination is a viable therapeutic approach for multiple myeloma.
- Further investigations will focus on novel dendritic cell immunization techniques, such as RNA transfection.
- The findings support continued development of Id/DC vaccination for multiple myeloma treatment.
Abstract:
Due to the existence of the truly specific tumor antigen idiotype in multiple myeloma and based on encouraging data from dendritic cell vaccinated B-cell non-Hodgkin's lymphoma (NHL) patients, dendritic cell-based vaccination was first initiated in myeloma patients in 1995. This overview will summarize published and ongoing clinical trials in patients with multiple myeloma who are treated with idiotype-based dendritic cell (Id/DC) vaccination. All groups of investigators have found that Id/DC vaccination of multiple-myeloma patients is feasible and that myeloma-specific immunity can be induced in heavily pretreated individuals. In future trials, new dendritic cell-based immunization strategies will be investigated based on techniques like RNA transfection of DC.
